| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Eur J Clin Pharmacol] 2022 Feb; Vol. 78 (2), pp. 205-214. <i>Date of Electronic Publication: </i>2021 Oct 01.
- MeSH Terms: Anticoagulants / *adverse effects ; Apolipoproteins E / *genetics ; Asian People / *genetics ; Hemorrhage / *chemically induced ; Warfarin / *adverse effects ; Adult ; Aged ; Amiodarone / pharmacology ; Anti-Arrhythmia Agents / pharmacology ; Body Surface Area ; Body Weight ; China ; Cytochrome P-450 Enzyme Inhibitors / pharmacology ; Ethnicity ; Female ; Genotype ; Humans ; International Normalized Ratio ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Retrospective Studies ; Sociodemographic Factors
- References: January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 140(2):e125–e151. https://doi.org/10.1161/CIR.0000000000000665. ; Crader MF, Johns T, Arnold JK (2020) Warfarin Drug Interactions. StatPearls. ; Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026. (PMID: 10.1016/j.chest.2015.11.02626867832) ; Hering D, Piper C, Bergemann R, Hillenbach C, Dahm M, Huth C, Horstkotte D (2005) Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest 127:53–59. https://doi.org/10.1378/chest.127.1.53. ; Akhtar RP, Abid AR, Zafar H, Khan JS (2009) Anticoagulation in patients following prosthetic heart valve replacement. Ann Thorac Cardiovasc Surg 15:10–17. https://doi.org/10.1177/021849230701500606. (PMID: 10.1177/02184923070150060619262444) ; Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long-term treatment. Blood 96(5):1816–1819. https://doi.org/10.1182/blood.V96.5.1816.h8001816_1816_1819. (PMID: 10.1182/blood.V96.5.1816.h8001816_1816_181910961881) ; Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha F, Kimmel SE (2007) Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81(5):742–747. https://doi.org/10.1038/sj.clpt.6100144. (PMID: 10.1038/sj.clpt.610014417329985) ; Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 100(2):229–239. https://doi.org/10.1160/TH07-09-0552. (PMID: 10.1160/TH07-09-055218690342) ; Jorgensen AL, Al-Zubiedi S, Zhang JE, Keniry A, Hanson A, Hughes DA, van Eker D, Stevens L, Hawkins K, Toh CH, Kamali F, Daly AK, Fitzmaurice D, Coffey A, Williamson PR, Park BK, Deloukas P, Pirmohamed M (2009) Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: A prospective study. Pharmacogenet Genom 19(10):800–812. https://doi.org/10.1097/FPC.0b013e3283317ab5. ; Molden E, Okkenhaug C, Ekker SE (2010) Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. Eur J Clin Pharmacol 66(5):525–530. https://doi.org/10.1007/s00228-010-0813-6. (PMID: 10.1007/s00228-010-0813-620354686) ; Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan HH, Lin QX, Yang M, Lin SG (2012) Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genom 22(3):176–182. https://doi.org/10.1097/FPC.0b013e32834f45f9. (PMID: 10.1097/FPC.0b013e32834f45f922198820) ; Wadelius M, Chen LY, Lindh JD, Eriksson N, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784–792. https://doi.org/10.1182/blood-2008-04-149070. ; Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321. https://doi.org/10.1038/sj.clpt.6100290. (PMID: 10.1038/sj.clpt.610029017653141) ; Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690–1698. https://doi.org/10.1001/jama.287.13.1690. ; Wu KK, Aleksic N, Ahn C, Boerwinkle E, Folsom AR, Juneja H (2001) Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation 103(10):1386–1389. https://doi.org/10.1161/01.CIR.103.10.1386. (PMID: 10.1161/01.CIR.103.10.138611245641) ; Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA (1997) Thrombomodulin gene mutations associated with myocardial infarction. Circulation 96(1):15–18. https://doi.org/10.1161/01.CIR.96.1.15. (PMID: 10.1161/01.CIR.96.1.159236408) ; Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6(2):115–138. https://doi.org/10.1517/14622416.6.2.115. ; Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473–3478. https://doi.org/10.1073/pnas.050585397. (PMID: 10.1073/pnas.0505853971071671916264) ; Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, Yoshimura K, Sakai T, Shirasaka D, Tamura T, Aoyama N, Kasuga M, Okumura K (2003) MDR1Genotype-Related Duodenal Absorption Rate of Digoxin in Healthy Japanese Subjects. Pharm Res (Dordrecht) 20(4):552–556. https://doi.org/10.1023/A:1023282312757. (PMID: 10.1023/A:1023282312757) ; Tavares LC, Marcatto LR, Soares RAG, Krieger JE, Pereira AC, Santos PCJL (2018) Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients. Front Pharmacol 9:542. https://doi.org/10.3389/fphar.2018.00542. (PMID: 10.3389/fphar.2018.00542298756685975540) ; De Oliveira Almeida VC, De Souza Ferreira AC, Ribeiro D, Gomes Borges KB, Salles Moura Fernandes AP, Brunialti Godard AL (2011) Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J Thromb Haemostasis 9(10):2120–2122. https://doi.org/10.3389/fphar.2018.00542. ; Li W, Zhao P, Chen L, Lai X, Shi G, Li L, Dong J (2020) Impact of CYP2C9, VKORC1, ApoE and ABCB1 Polymorphisms on Stable Warfarin Dose Requirements in Elderly Chinese Patients. Pharmacogenomics 21(2):101–110. https://doi.org/10.2217/pgs-2019-0139. (PMID: 10.2217/pgs-2019-013931854268) ; Gage BF, Eby CS (2004) The genetics of vitamin K antagonists. Pharmacogenomics J 4(4):224–225. https://doi.org/10.1038/sj.tpj.6500258. (PMID: 10.1038/sj.tpj.650025815148502) ; Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5(4):262–270. https://doi.org/10.1038/sj.tpj.6500313. (PMID: 10.1038/sj.tpj.650031315883587) ; Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121(1):23–34. https://doi.org/10.1007/s00439-006-0260-8. ; Li B, Liu R, Wang C, Ren C, Zhang S, Zhang F, Zhang J, Wei SLY, Liu W, Song B, Xinan Wu (2019) Impact of Genetic and Clinical Factors on Warfarin Therapy in Patients Early After Heart Valve Replacement Surgery. Eur J Clin Pharmacol 75(12):1685–1693. https://doi.org/10.1007/s00228-019-02747-5. (PMID: 10.1007/s00228-019-02747-531444512) ; Kishino S, Nomura A, Di ZS, Sugawara M, Iseki K, Kakinoki S, Kitabatake A, Miyazaki K (1995) Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol 35(5):510–514. https://doi.org/10.1002/j.1552-4604.1995.tb04096.x. (PMID: 10.1002/j.1552-4604.1995.tb04096.x7657852) ; Eap CB, Cuendet C, Baumann P (1988) Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J Pharm Pharmacol 40(11):767–770. https://doi.org/10.1111/j.2042-7158.1988.tb05169.x. (PMID: 10.1111/j.2042-7158.1988.tb05169.x2907555) ; Wang LS, Shang J, Shi SY, Zhang YQ, Lin J, Guo ZH, Wang YC, Tang J, Liu J, Liu YZ, Li Z, Tan ZR, Zhou HH, Jiang HH, Xie HT (2013) Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage. Eur J Clin Pharmacol 69(5):1113–1120. https://doi.org/10.1007/s00228-012-1448-6. (PMID: 10.1007/s00228-012-1448-623208322) ; Timson DJ (2017) Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism. Curr Drug Targets 18(5):500–510. https://doi.org/10.2174/1389450116666150722141906. (PMID: 10.2174/138945011666615072214190626201483) ; Li J, Yang W, Xie Z, Kun Yu, Chen Y, Cui K (2018) Impact of VKORC1, CYP4F2 and NQO1 Gene Variants on Warfarin Dose Requirement in Han Chinese Patients With Catheter Ablation for Atrial Fibrillation. BMC Cardiovasc Disord 18(1):96. https://doi.org/10.1186/s12872-018-0837-x. (PMID: 10.1186/s12872-018-0837-x297763865960187) ; Wennberg P, Wensley F, Di Angelantonio E, Johansson L, Boman K, Rumley A, Lowe G, Hallmans G, Danesh J, Jansson JH (2012) Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res Jan 129(1):68–73. https://doi.org/10.1016/j.thromres.2011.05.015. (PMID: 10.1016/j.thromres.2011.05.015) ; Vene N, Mavri A, Kosmelj K, Stegnar M (2003) High d-dimer levels predict cardiovascularevents in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 90(6):1163–1172. https://doi.org/10.1160/TH03-06-0363. (PMID: 10.1160/TH03-06-036314652652) ; Lind M, Boman K, Johansson L, Nilsson TK, Järvholm LS, Jansson JH (2014) D-dimer predicts major bleeding, cardiovascular events and all-cause mortality during warfarin treatment. Clin Biochem 47(7–8):570–573. https://doi.org/10.1016/j.clinbiochem.2014.03.003. ; Abdi AA, Osman A (2017) Prevalence of common hereditary risk factors for thrombophilia in Somalia and identification of a novel Gln544Arg mutation in coagulation factor V. J Thromb Thrombolysis 44(4):536–543. https://doi.org/10.1007/s11239-017-1543-8. (PMID: 10.1007/s11239-017-1543-8288892005658450) ; Chen M, Mao BY, Wang D, Cheng X, Xu CX (2016) Association between rs1801133 polymorphism and risk of adult ischemic stroke: Meta-analysis based on case–control studies. Thromb Res 137:17–25. https://doi.org/10.1016/j.thromres.2015.11.037. ; Ezigbo ED, Ukaejiofo EO, Nwagha TU (2016) Molecular characterization of exon 28 of von Willebrand′s factor gene in Nigerian population. Niger J Clin Pract 20(2):235–238. https://doi.org/10.4103/1119-3077.197002. (PMID: 10.4103/1119-3077.197002) ; Ma C, Zhang Y, Qiang Xu, Yang J, Zhang Y, Gao L, Bin Xu, Wang H, Li Y, Caiyi Lu, Yin T (2012) Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol 96(6):719–728. https://doi.org/10.1007/s12185-012-1205-8. (PMID: 10.1007/s12185-012-1205-823104259) ; Tavares LC, Duarte NE, Marcatto LR, Soares RA, Krieger JE, Pereira AC, Santos PC, Lima J (2018) Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population. Eur J Clin Pharmacol 74(12):1555–1566. https://doi.org/10.1007/s00228-018-2528-z. ; Bai Y, Chen J, Sun K, Wang Y, Hui R (2012) A Functional Variant in Promoter Region of Platelet-Derived Growth factor-D Is Probably Associated with Intracerebral Hemorrhage. J Neuroinflammation 9:26. https://doi.org/10.1186/1742-2094-9-26. (PMID: 10.1186/1742-2094-9-26222894413307028) ; Bergrem A, Dahm AE, Jacobsen AF, Mowinckel MC, Sandvik L, Sandset PM (2011) Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br J Haematol 154(2):241–247. https://doi.org/10.1111/j.1365-2141.2011.08712.x. ; Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS (2008) Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 8(1):53–60. https://doi.org/10.1038/sj.tpj.6500445. (PMID: 10.1038/sj.tpj.650044517325732) ; Liu R, Zhang K, Gong ZZ, Shi XM, Zhang Q, Pan XD, Dong R (2016) Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese population. Lipids Health Dis 15(1):34. https://doi.org/10.1186/s12944-016-0205-8. (PMID: 10.1186/s12944-016-0205-8269120744765220) ; He S, Zhang H, Cao Y, Nian F, Chen H, Chen W, Auchoybur ML, Yin L, Tao Z, Tang S, Chen X (2018) Association between apolipoprotein E genotype and warfarin response during initial anticoagulation. Biomed Pharmacother 101:251–256. https://doi.org/10.1016/j.biopha.2018.02.095. ; Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298(11):1300–1311. https://doi.org/10.1001/jama.298.11.1300. (PMID: 10.1001/jama.298.11.130017878422) ; Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS (2007) Apolipoprotein E genotype and warfarin dosing among caucasians and African Americans. Pharmacogenom J 8(1):53–60. https://doi.org/10.1038/sj.tpj.6500445. (PMID: 10.1038/sj.tpj.6500445) ; Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, Mcginnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121(1):23–34. https://doi.org/10.1007/s00439-006-0260-8. (PMID: 10.1007/s00439-006-0260-817048007)
- Grant Information: 2018Y0037 Natural Science Foundation of Fujian Province
- Contributed Indexing: Keywords: Bleeding complications; Demographic characteristics; Gene polymorphism; Han population; Warfarin
- Substance Nomenclature: 0 (Anti-Arrhythmia Agents) ; 0 (Anticoagulants) ; 0 (ApoE protein, human) ; 0 (Apolipoproteins E) ; 0 (Cytochrome P-450 Enzyme Inhibitors) ; 5Q7ZVV76EI (Warfarin) ; N3RQ532IUT (Amiodarone)
- Entry Date(s): Date Created: 20211001 Date Completed: 20220225 Latest Revision: 20221207
- Update Code: 20240513
|
